Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Perrigo (PRGO)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$15.71-0.76%
Close 2026-11-05 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
2.40 → 2.34 EPS · FY ending Dec 31, 2027 · 3 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 3; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for PRGO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce debt using proceeds from divestitures | Perrigo aims to cut debt using €306 million from sales. | Intact | Proceeds from divestitures fall short of €300 million by Q1 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a turnaround-oriented consumer health business, not a steady earnings compounder today. The multi-year view remains intact, with the recent signal improving from mixed to mildly favorable, but evidence of a broad financial recovery is limited.
The valuation evidence points to PRGO being cheap versus peers, while the expectations gap is negative, suggesting expectations remain cautious. The valuation model has medium confidence, and no fragility warnings were triggered.
Near term, management has reaffirmed guidance and the latest reported earnings event was positive, but core net sales and adjusted operating margin declined year over year in 2026-Q2. Debt reduction is tangible, while the Three-S plan and portfolio shift show mixed financial delivery; losses and erratic earnings remain important risks.
The multi-year thesis depends on management stabilizing sales and margins while continuing to simplify the business and reduce debt. Near term, a guidance cut or further labor-market weakness would add pressure, while continued strength from healthcare peers could support the sector backdrop.
Over the next one to three years, PRGO’s long-term thesis rests on turning strategic actions and debt progress into steadier financial results. The current setup is cautiously improved, but losses, declining core results, and elevated risk keep the evidence mixed. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company keeps paying steady dividends of $0.29 per share. |
| Intact |
| Dividend per share falls below $0.29 in next 4 quarters |
Dividend per share: $0.29 per share FY2026-Q3; GAAP. Published target: Dividend per share >= $0.29 in next 4 quarters. Target period is not explicitly aligned with this observation. Nov 4, 20260.29 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Improve operating cash flow from negative $114 million | A primary condition in Perrigo's published investment case. The stated target is Operating cash flow >= $0 in FY 2026. | Under Pressure | Operating cash flow remains negative through FY 2026 | Cash from operations: $138.3M FY2026-Q2; GAAP. Published target: Operating cash flow >= $0 in FY 2026. Target period ends 2026-12-31; this observation covers 2026-Q2. Aug 5, 2026138,300,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain operating margin near 13% | It plans profit margins near 13% in 2026. | Intact | Operating margin falls below 12.5% in FY 2026 | Operating margin: 2.34% FY2026-Q3; GAAP. Published target: Operating margin >= 12.5% in FY 2026. Target period ends 2026-12-31; this observation covers 2026-Q3. Nov 4, 20262.336638 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$2.37 → $2.34 · observed estimates
$4.09B → $4.09B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $2.37 | $4,087,071,300 | 3 / 4 |
| 2026-07-25 | $2.37 | $4,087,071,300 | 3 / 4 |
| 2026-07-26 | $2.36 | $4,098,475,000 | 5 / 4 |
| 2026-07-27 | $2.36 | $4,098,475,000 | 5 / 4 |
| 2026-07-28 | $2.36 | $4,098,475,000 | 5 / 4 |
| 2026-07-29 | $2.36 | $4,098,475,000 | 5 / 4 |
| 2026-07-30 | $2.37 | $4,087,071,300 | 3 / 4 |
| 2026-07-31 | $2.37 | $4,096,433,333 | 3 / 4 |
| 2026-08-01 | $2.37 | $4,096,433,333 | 3 / 4 |
| 2026-08-02 | $2.37 | $4,105,575,000 | 5 / 4 |
| 2026-08-03 | $2.37 | $4,096,433,333 | 3 / 4 |
| 2026-08-04 | $2.37 | $4,096,433,333 | 3 / 4 |
| 2026-08-05 | $2.37 | $4,096,433,333 | 3 / 4 |
| 2026-08-06 | $2.37 | $4,105,575,000 | 5 / 4 |
| 2026-08-07 | $2.40 | $4,074,932,233 | 3 / 4 |
| 2026-08-08 | $2.40 | $4,089,331,130 | 5 / 4 |
| 2026-08-09 | $2.40 | $4,089,331,130 | 5 / 4 |
| 2026-08-10 | $2.40 | $4,074,932,233 | 3 / 4 |
| 2026-08-12 | $2.40 | $4,089,331,130 | 5 / 4 |
| 2026-08-13 | $2.40 | $4,089,331,130 | 5 / 4 |
| 2026-08-14 | $2.40 | $4,074,932,233 | 3 / 4 |
| 2026-08-15 | $2.40 | $4,074,932,233 | 3 / 4 |
| 2026-08-16 | $2.40 | $4,074,932,233 | 3 / 4 |
| 2026-08-17 | $2.40 | $4,074,932,233 | 3 / 4 |
| 2026-08-18 | $2.40 | $4,074,932,233 | 3 / 4 |
| 2026-08-19 | $2.40 | $4,074,932,233 | 3 / 4 |
| 2026-08-20 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-08-21 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-08-22 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-08-23 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-08-24 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-08-25 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-08-26 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-08-27 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-08-28 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-08-29 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-08-30 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-08-31 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-01 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-02 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-03 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-04 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-05 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-06 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-07 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-08 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-09 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-10 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-11 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-12 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-13 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-14 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-15 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-16 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-17 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-18 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-19 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-20 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-21 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-22 | $2.43 | $4,074,900,000 | 3 / 4 |
| 2026-09-23 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-09-24 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-09-25 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-09-26 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-09-27 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-09-28 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-09-29 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-09-30 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-01 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-02 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-03 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-04 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-05 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-06 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-07 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-08 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-09 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-10 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-11 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-12 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-13 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-14 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-15 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-16 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-17 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-18 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-19 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-20 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-21 | $2.40 | $4,074,900,000 | 3 / 4 |
| 2026-10-22 | $2.39 | $4,067,566,667 | 3 / 4 |
| 2026-10-23 | $2.39 | $4,067,566,667 | 3 / 4 |
| 2026-10-24 | $2.39 | $4,067,566,667 | 3 / 4 |
| 2026-10-25 | $2.39 | $4,067,566,667 | 3 / 4 |
| 2026-10-26 | $2.39 | $4,067,566,667 | 3 / 4 |
| 2026-10-27 | $2.39 | $4,067,566,667 | 3 / 4 |
| 2026-10-28 | $2.39 | $4,067,566,667 | 3 / 4 |
| 2026-10-29 | $2.39 | $4,067,566,667 | 3 / 4 |
| 2026-10-30 | $2.34 | $4,089,533,550 | 3 / 4 |
| 2026-10-31 | $2.34 | $4,089,533,550 | 3 / 4 |
| 2026-11-01 | $2.34 | $4,089,500,000 | 3 / 4 |
| 2026-11-02 | $2.34 | $4,089,500,000 | 3 / 4 |
| 2026-11-03 | $2.34 | $4,089,500,000 | 3 / 3 |
| 2026-11-04 | $2.34 | $4,089,500,000 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.